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NEUROPROTECTION IN ACUTE STROKE:
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SUMMARY · Efficacious treatment of acute stroke is a major challenge in modern medicine. Thera-
peutic neuroprotection acting towards minimization of ischemic neuronal injury in penumbral tissue
in the regions of reduced cerebral blood flow seems to be an appealing concept in the treatment of
acute stroke and brain trauma. The ‘ischemic cascade’, a complex mechanism of metabolic events
initiated by brain ischemia, offers many pathways by which the neuroprotective agents may act. Time
to treatment remains a major limiting factor for many potential neuroprotective agents. Although
the exact therapeutic window is not known, evidence from many animal models and clinical research
suggest that neuroprotective therapy can only be efficacious if administered very early after the onset
of ischemia. Various neuroprotective agents have been tested in many clinical stroke trials during the
past 20 years. Large phase III clinical trials of several classes of neuroprotectants (mainly NMDA
receptor antagonists, free radical scavengers, and calcium channel blockers) have recently failed to
demonstrate efficacy of neuroprotection. After initial disappointment, the active research continues
and some new exciting neuroprotective models emerge on the horizon.
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Introduction
Stroke is the most common neurological emergency
encountered by physicians worldwide. It is only since the
last decade that stroke has been recognized as an urgent
condition. The concept of strokes as ‘brain attacks’ has
gained wide popularity, and has motivated many basic and
clinical researchers to search for its efficacious treatment.
In the ‘decade of the brain’, many clinical trials of thera-
peutic agents for the treatment of acute brain attacks were
conducted. An efficacious treatment of stroke is still a
major challenge in modern medicine.
Clinical trials in stroke prevention have been more
successful in demonstrating the benefits of treatment of
stroke risk factors than from treatment of acute stroke
itself. Anti-platelet agents in primary and secondary pre-
vention of stroke, and carotid endarterectomy for second-
ary prevention of stroke are well established therapies. The
early preventive measures and treatment for cerebrovas-
cular disease have contributed to the decrease in the preva-
lence of overall mortality from both coronary artery dis-
ease and stroke1.
A Window of Opportunity for Intervention
Brain ischemia initiates an ‘ischemic cascade’, a com-
plex sequence of metabolic events from energy depletion,
involvement of the generation of nitrogen and oxygen free
radicals, through excitation of NMDA receptors and in-
tracellular influx of calcium, to the induction of apoptotic
and necrotic pathways. All of these mechanisms produce
brain damage that occurs within few minutes to hours
after transient brain ischemia, or in the penumbral region
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of infarcts after permanent ischemia. The mode of cell
death that prevails probably depends on the severity, du-
ration and precise nature of the ischemic injury. However,
all of these metabolic events initiated by brain ischemia
may be the potential sites of possible action of a neuro-
protective agent.
The National Institute of Neurological Diseases and
Stroke (NINDS) tissue plasminogen activator (tPA)
stroke study has demonstrated the pivotal role of time
as a limiting factor for the successful treatment of stro-
kes2. Rodent models of acute middle cerebral artery oc-
clusion consistently demonstrate that reperfusion within
3 hours of arterial occlusion can limit the size of the re-
sulting infarct and improve other measures of outcome3.
These studies also show that reperfusion after 3 hours
has little benefit and may provoke the development of
malignant cerebral edema with hemorrhagic transforma-
tion of the ischemic brain regions (‘reperfusion injury’)4.
Time to treatment remains a major limiting factor
with these animal models, demonstrating that neuropro-
tective therapy is only efficacious when initiated as a pre-
treatment or early after focal ischemia2,3. The exact thera-
peutic time window is unknown, but evidence suggests
that infarct volume can only be reduced if neuroprotective
measures are initiated within 1 to 2 hours from the onset
of ischemia5. The rationale for combination therapy in-
cludes the inhibition of glutamate induced excitotoxicity,
reduction or inhibition of potential neuronal toxic com-
pounds such as nitric oxide or free radicals, and inhibition
of apoptosis (‘programmed cell death’), which are involved
in altered neuronal and microglial gene structure and ex-
pression. These factors have an important deleterious ef-
fect on the ‘reperfusion injury’ that may be observed with
thrombolysis. A strategic combination of neuroprotection
and thrombolytic therapy may also prolong the ‘window
of opportunity’5. ‘Time is brain’, so is the underlying
pathomechanism.
Neuroprotective Agents in Cerebral Ischemia
Therapeutic neuroprotection in acute ischemic strokes
seems to be an appealing concept which may potentially
increase the therapeutic window of opportunity for throm-
bolytic treatment. Large phase III clinical trials of several
different neuroprotective agents including nimodipine and
lubeluzole have, however, failed miserably (Table 1)6-9.
The latest study of a neuroprotectant, gavestinel, in
acute stroke was completed last year (GAIN Americas:
Glycine antagonist in neuroprotection)10. In the press
release on April 4, 2001, Dr. Ralph L. Sacco (New York),
the principal investigator of the GAIN study, reported
that stroke patients treated within 6 hours with an experi-
mental drug, gavestinel, showed no improvement 3
months after stroke compared with placebo. This trial was
the largest study of a neuroprotective agent for acute
stroke in North America. “While the finding was a dis-
appointment, in light of the growing belief that rapid ac-
tion to counter the damage of acute stroke might improve
outcomes for patients, the strategy of neuroprotective
drugs to treat ischemic stroke still remains a significant
area for investigation.” The GAIN trial was a randomized,
double-blind, placebo-controlled trial that enrolled 1,367
patients with acute ischemic stroke within 6 hours of onset
at 132 hospital centers in the United States and Canada.
Thirty-nine percent of the gavestinel treated patients were
independent at 3 months, compared with 37 percent of
the patients administered placebo. Even among 241 pa-
tients treated within 4 (rather than 6) hours of stroke
onset, no beneficial effect for gavestinel was recorded.
Neither was any benefit of gavestinel demonstrated
among 333 patients treated with tPA. On the other hand,
gavestinel had no serious side effects. This study corrobo-
rated the results of a similar study of gavestinel conducted
in Europe, Australia and Asia (GAIN International)11.
Dr. Sacco and his colleagues conclude that, while this
agent was not efficacious, “we still believe neuroprotection
remains a viable strategy for acute stroke treatment and
should continue to be studied.” Moreover, the completed
trials have provided large evidence of safety data, allow-
ing for some understanding of which agents may be well
tolerated by stroke patients and continue to be investi-
gated12.
Although many researchers have lost their enthusiasm
for neuroprotection, many more still think there is hope
for neuroprotection, especially with better methods of
conducting clinical trials. The long list of clinical trials
that failed with neuroprotective agents have raised con-
cerns about how to proceed best for the future develop-
ment of such interventions. The Stroke Therapy Aca-
demic Industry Roundtable (STAIR) have published rec-
ommendations for standards of preclinical and clinical
neuroprotective and restorative drug development13,14.
This conference of academicians and industry represen-
tatives was convened to suggest guidelines for the preclini-
cal and clinical evaluation of neuroprotective drugs, and
to recommend to potential clinical investigators the data
they should review to reassure themselves that a particu-
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Table 1. Neuroprotective agents that proved a failure in clinical trials for acute stroke*
Mechanism of action Agent
Antagonists of voltage sensitive calcium channels Nimodipine
Flunarazine
Darodopine
Excitatory amino acid antagonists Monoganglioside GM1




Competitive antagonists of NMDA receptor Selfotel
Antagonists of AMPA receptors





Antagonists of glycine regulatory sites Gavestinel (GV150526)
Inhibitors of glutamate release Lamotrigine
BW 619 C89
Scavengers of free radicals Tirilazid neylate
Antibody to intercellular leukocyte Enlimomab
Enhancement of the effect of GABA-A receptors Clomethiazole
Inhibition of nitric oxide synthetase Lubeluzole
Growth factors Basic fibroblast growth factor
Stabilization of neuronal membranes Citicoline
Opioid antagonist Nalmefene
Naloxone
*Selection made from ref. nos. 6-9, 15, and Washington University Internet site: University Stroke Trials Directory
lar neuroprotective drug has a reasonable chance to suc-
ceed in an appropriately designed clinical trial. The most
important points for clinical investigators to assess before
considering embarking upon a trial of a new neuropro-
tective agent include an appropriate dose-response curve
analysis, time window studies, proper blinded animal
studies in preferably two species and reproducible treat-
ment effect in two laboratories, and outcome measures
with infarct volume and functional assessment. Without
a rigorous, robust and detailed preclinical evaluation, it is
unlikely that novel neuroprotective drugs will prove effi-
cacious when tested in large, time-consuming and expen-
sive clinical trials.
Most neuroprotectants act on one selected process in
the ischemic cascade, which may not be sufficient to re-
duce brain damage as other processes continue. Current
neuroprotective strategies target mainly ischemia induced
excitotoxic mechanisms, ischemia induced nitric oxide
associated neuronal damage, and ischemia associated neu-
ronal cellular membrane damage (Table 2)6-8,15. Drugs
that act at different levels of the ischemic cascade may be
more powerful as neuroprotectants15. In the future, thera-
peutic neuroprotective strategies may also include agents
that prevent apoptosis and other redundant neurotoxic
mechanisms that become active with cerebral ischemia. A
combination of several different neuroprotective agents
that act on several steps in the excitotoxic cascade in the
form of a ‘stroke cocktail’ has only theoretical advantages
but it may also be a rational step forward for better treat-
ment during the ‘ischemic cascade’ of events in acute
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stroke. Meanwhile, this concept is on hold as the Food and
Drug Administration does not allow the use of a combi-
nation of two or more investigational drugs in clinical tri-
als.
Currently, hypothermia and drugs with a potential to
enhance recovery after acute ischemic stroke seem to be
the most promising approaches. Randomized clinical tri-
als of the effect of hypothermia (body surface cooling, or
more recently endovascular cooling catheters) in acute
stroke are just underway in many institutions9. Addition-
ally, the STAIR recommendations have provided a set of
overall guidelines for the development of drugs and in-
terventions in the field with great potential but limited
positive trials.
Conclusion
Time as well as complex pathophysiology continue to
be the major limiting factors for the successful treatment
of acute ischemic strokes. At present, thrombolytic therapy
remains the only approved form of treatment for acute is-
chemic strokes. However, phase II and III trials of several
neuroprotective agents that are currently underway give us
hope that in the near future all patients with acute stroke
will receive some form of intervention that may help limit
the disability and devastation caused by stroke.
Table 2. Neuroprotective agents currently investigated in clinical trials for acute stroke*
Mechanism of action Agent
Scavengers of free radicals NYX 059
Noncompetitive NMDA antagonists Magnesium sulfate
AR-R 15896 AR
Agonists of serotonin (5HT1A receptor) BAY 3702
Sodium channel blocker Sipatrigine
Potassium channel blocker BMS-204352 (MaxiPost)
Membrane activated calcium chelator DP-b99
Neutrophil inhibitory factor (CD11b/CD18 receptor) Corleukin (UK-279,276)
AMPA receptor antagonist YM872 (in combination with tPA: ARTIST+)
Nitric oxide inhibitor Glyceryl trinitrate
Membrane stabilizer Piracetam
Early GABA-ergic activation Diazepam
Recovery: Transplant LGE cells (porcine neuronal cells) Diacrin
*Selection made from ref. nos. 6-9, and Washington University Internet site: University Stroke Trials Directory
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Saæetak
NEUROZA©TITA U AKUTNOM MOÆDANOM UDARU: IMA LI JO© NADE?
T. Rundek, R.L. Sacco i V. Demarin
UËinkovito lijeËenje akutnog moædanog udara velik je izazov u suvremenoj medicini. Terapijska neuroza¹tita kojom bi se
ishemijsko neuronsko o¹teÊenje u tkivu penumbre u podruËjima smanjenog moædanog krvnog protoka svelo na najmanju
moguÊu mjeru Ëini se primamljivom zamisli u lijeËenju akutnog moædanog udara i moædane traume. ‘Ishemijska kaskada’,
odnosno sloæen mehanizam metaboliËnih dogaðaja ¹to ih potiËe moædana ishemija, nudi mno¹tvo putanja kojima bi neuroza¹titna
sredstva mogla djelovati. Vrijeme proteklo do poËetka lijeËenja ostaje glavnim ograniËavajuÊim Ëimbenikom za mnoga potencijalna
neuroza¹titna sredstva. Iako toËan terapijski prozor nije poznat, rezultati dobiveni u mnogobrojnim æivotinjskim modelima i
kliniËkim istraæivanjima ukazuju na to da bi neuroza¹titna terapija mogla biti uËinkovita samo ako se dade vrlo rano nakon
nastupa ishemije. Tijekom posljednjih 20 godina razliËita neuroza¹titna sredstva ispitivana su u moædanom udaru u mnogim
kliniËkim pokusima. Nedavno provedeni veliki kliniËki pokusi III. faze s nekoliko skupina neuroza¹titnih sredstava (uglavnom
antagonista NMDA receptora, ËistaËa slobodnih radikala  i blokatora kalcijevih kanala) nisu dokazali uËinkovitost neuroza¹tite.
Nakon prvotnog razoËaranja djelatna se istraæivanja nastavljaju, a na obzoru se naziru neki novi i uzbudljivi modeli neuroza¹tite.
KljuËne rijeËi: Cerebrovaskularni udar, lijekovi; KliniËki pokus; Ishod lijeËenja; Neuroza¹titna sredstva
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